Homepage Top Section2

Nexus has entered into an agreement with Wisconsin’s village Pleasant Prairie for the development of a sterile injectable manufacturing facility. Expected to be completed in 10 years, the

Velocity Pharmaceutical Development, along with Dr John Nestor, had established Spitfire for the development of SP-1373, a potent GLP-1/Glucagon receptor co-agonist to treat non-alcoholic steatohepatitis (NASH). Under the

The option obtained by MorphoSys gives it the rights to globally develop and commercialise Vivoryon’s family of QPCTL inhibitors, including the latter’s lead compound PQ912. Currently, PQ912 had

Pfizer and Sangamo Therapeutics revealed updated results from the Phase 1/2 Alta study, which demonstrated that SB-525 was generally well-tolerated and showed a dose-dependent increase in Factor VIII

The European approval for Libtayo is for such patients who are not eligible for curative surgery or curative radiation. The skin cancer drug was given the regulatory nod

The fusion protein, which is being developed for NASH, utilises the HyFc technology of Genexine. It has been developed in-house by South Korean pharma company. The fusion protein

The agency said that as the benefits of Evenity did not outweigh its risks, it recommended refusal of the drug’s marketing authorisation. The marketing authorisation application (MAA) of

The approval allows the drug firms to use Dupixent with other medicines for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not

As per terms of the deal, Allergan shareholders will secure 0.8660 AbbVie shares and $120.30 (£94.8) in cash for each Allergan share. The total consideration will be $188.24